Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (MFAG 22136)
First Online: 13 February 2019
Change Date: 25 February 2019
Change Type: Correction
Change Details: Following publication of the original article , the authors reported an error in the spelling of Lorenzo Dagna’s name.
Ethics approval and consent to participate
: Need for approval waived as canakinumab is approved by Italian regulating bodies for the treatment of AOSD. Patients gave their consent to drug administration and utilization of data in anonymous form for research purposes.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.